F-NaF, a positron emission tomography (PET) radiotracer of bone turnover, has shown potential as an imaging biomarker for assessing therapeutic response of bone metastases. This study aims to evaluate the repeatability of 18 F-NaF PET-derived SUV metrics in individual bone lesions from patients in a multicenter study.
Repeatability of 18 F-NaF PET/CT of SUVmax, SUVmean, and SUVtotal were similar between lesion-and patient-level regions of interest. We found significant differences in lesion-level and patient-level difference distributions between sites. These results can be used to establish NaF PET-based treatment response assessment criteria at the lesion-and patient-levels. NaF PET demonstrates repeatability levels useful for clinical quantification of bone lesion response to therapy.
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INTRODUCTION
Prostate cancer is distinct among solid tumors in that its advancement largely presents as clinically detectable osteoblastic bone metastases (1) . Currently there are no established tools to reliably and quantitatively measure functional changes in bone metastases in response to therapy (2) . The development of imaging biomarkers to measure response in bone can improve clinical care, particularly in advanced prostate cancer.
Radiolabeled sodium fluoride, 18 F-NaF, was first introduced by Blau et Tc (3) (4) (5) (6) . With recent technological advances in PET, NaF PET has been increasingly used for detecting bone metastases because of its higher specificity and sensitivity as compared to planar bone scintigraphy and SPECT (3, 4, (7) (8) (9) (10) . NaF PET shows potential for longitudinal disease assessment, as its standardized uptake values (SUV) in both normal and pathologic bone are representative of changes in bone metabolism (11) (12) (13) .
Repeatability of a biomarker, defined as the variation of repeated measurements in an experiment performed under the same conditions, is necessary to measure in order to accurately assess tumor response (14) . Repeatability of 18 F-FDG based on double baseline studies has been well studied, permitting the development of PET Response Criteria In Solid Tumors (15) (16) (17) . No such criterion exists for evaluating quantitative 18 F-NaF PET response.
A previous study evaluated the repeatability of NaF PET activity in bone uptake within the whole body (18) . However, repeatability can also be evaluated of individual bone lesion regions of interest (ROIs), allowing the assessment of how a tumor's response may uniquely contribute to the disease burden on the patient as a whole. The evaluation of repeatability of uptake in an individual lesion would allow for assessment of response heterogeneity across within the patient.
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Here we report on the first multi-center study assessing the repeatability of NaF PET uptake at the lesion-level. In addition, we compared the repeatability values between 3 different imaging sites in a multicenter trial.
METHODS

Patient population and study design
This was a prospective, non-randomized two-arm, multi-institutional pharmacodynamic imaging clinical trial with the primary objective to determine the repeatability of NaF A sample size of n=20 patients per site was proposed to evaluate repeatability. This sample size provided sufficient power (≥80%) to detect the anticipated excellent level of repeatability at each of the three study sites at the one-sided 0.0167 significance level.
Quantitative image acquisition
Test-retest NaF PET/CT whole-body scans were to be performed 2-5 days apart and prior to start of therapy. Patients were injected intravenously with a bolus of 111-185 MBq (3-5 mCi) of NaF and imaged 60 minutes post-injection for 3 minutes per bed position from feet to skull vertex. Scans at UWCCC and MSKCC were acquired on the Discovery VCT (GE Healthcare, Waukesha, WI) PET/CT scanner, and scans at NCI were acquired on the Gemini by on October 21, 2017. For personal use only. jnm.snmjournals.org Downloaded from (Philips Healthcare, Amsterdam, Netherlands) PET/CT scanner. PET images were attenuation and scatter-corrected.
Scanner harmonization
Quantitative harmonization of scanners was achieved to obtain equivalent image quality and quantitative accuracy across scanners. The GE scanners were harmonized to the Philips scanner. Harmonization was performed using a uniform phantom to measure the signal-to-noise ratio, and the National Electrical Manufacturers Association International Electrotechnical Commission body phantom. Absolute calibration was measured by the recovery coefficient, defined as the ratio of the mean measured activity concentration in to the true activity concentration in the ROI. Difference between scanners in recovery coefficient and signal-tonoise ratio was minimized by systemically varying reconstruction parameters such as number of iterations, number of subsets, and post-reconstruction filter.
ROI definition
Automatic identification and segmentation of lesions was achieved with a CT mask applied to exclude soft tissue uptake followed by a SUV>15 g/mL threshold to exclude additional activity with low statistical likelihood of being malignant (18, 19) . Lesion contours were verified by an experienced nuclear medicine physician on PET/CT images and contours smaller than 1.5 cm 3 as measured by PET volume were excluded. Matching of corresponding lesions between paired scans was performed automatically using articulated registration (20) .
Two levels of SUV analysis were performed: lesion-level analysis, where SUV metrics were extracted from each individual lesion ROI (iROI), and patient-level analysis, where all lesions for a patient were grouped into a single patient ROI (pROI) before SUV analysis. For both ROI levels, SUVmax is defined as the maximum SUV of the ROI. SUVtotal is defined as the total summed SUV of the ROI normalized to voxel volume. SUVmean of iROI is the mean SUV within the ROI and SUVmean of pROI is the mean of SUVmean of all lesions in the patient. The two by on October 21, 2017. For personal use only. jnm.snmjournals.org Downloaded from different levels of analysis will be differentiated using the notation iSUV for individual lesion-level SUV metrics, and pSUV for patient-level SUV metrics.
Statistical analysis
Primary outcome measures for evaluating repeatability of SUV metrics were intra-class correlation coefficient (ICC) and repeatability coefficient (RC). RC was calculated at α= 0.05.
ICC was estimated using a two-way mixed effects model.
Additional statistical measures for evaluating repeatability of quantitative imaging biomarkers as recommended by the Quantitative Imaging Biomarkers Alliance or previously reported in literature were investigated (21) . Test-retest agreement for each ROI was evaluated with the Bland-Altman analysis method for repeated observations (22, 23) .
Because the distribution of SUV metrics were highly skewed, statistical analyses were performed on natural-log transformations of measurements (21, 22, 24) . Statistical analysis was conducted using MATLAB (MathWorks, Natick, MA) version R2014B, R (R Development Core Team) version 3.0, and SPSS (IBM Corp, Armonk, NY) version 22.
For lesion-level analysis, analysis of variance with repeated measurements was used to account for correlations between multiple lesions within the same patient and used to calculate , standard deviation of differences between test-retest measurements (23).
Coefficient of variation (CV) of within-subject measurements was calculated as the ratio of  to the grand mean. The critical percentage difference (CPD) is the minimum percentage change needed to designate a change as significant (18), defined as exp 1.96√2 1 100%.
Limits of agreement (LOA95%) were calculated for the ratio of the test (mA) to retest (mB) measurements. Within LOA95% lies the ratio of mB/mA with a probability of 95%:
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One-way analysis of variance with pairwise comparisons and two-sample t-test were used to assess whether the bias for each metric significantly differed between sites. Two-sample F-tests were used to evaluate if variability across sites.
RESULTS
A total of 411 NaF-avid bone lesions from 35 mCRPC patients imaged at one of three sites were evaluated (Fig. 1 ). Patients were injected intravenously with 159.8±9.7 MBq of NaF and test-retest NaF PET/CT whole-body scans were performed 63±7 minutes post-injection (3±2 days apart). Dose infiltration near the injection site was minimal in all scans. Two of 35 patients received partial whole-body scans due to patient repositioning during the scan. Lesion and patient characteristics are summarized in Table 1 Relative difference between test-retest scans tend to be slightly greater at the lesionlevel than at the patient-level. For all metrics, distributions of relative difference were narrower for pROI than iROI (Fig. 2) . SUVmean had the smallest relative difference for both ROIs. For iROI, iSUVmean was most repeatable (inner-quartile range, IQR=2.5%) followed by SUVmax (IQR=4.
.0%), followed by pSUVtotal (IQR=2.6%), and pSUVmax (IQR=3.3%).
Figs. 3 and 4 contain Bland-Altman plots, which demarcate RC. For lesion-level SUV metrics, iSUVmean had the smallest variability (RC=0.13), followed by iSUVmax (RC=0.27), and iSUVtotal (RC=0.49). Fig. 4 contains Bland-Altman plots for each patient-level SUV metric.
Similarly, pSUVmean was most repeatable (RC=0.10), followed by pSUVmax (RC=0.24) and pSUVtotal (RC=0.36). Both lesion-level and patient-level distributions have approximately normal distributions and heteroscedasticity.
According to RC, CV, and CPD, SUVmean was the most repeatable followed by SUVmax, and SUVtotal at both the lesion-and patient-levels (Tables 3 and 4 ). The LOA95% of the ratio of test-retest measurements define the interval containing the ratio of test-retest measurements for each imaging metric. LOA95% from each site were widely overlapping for all three metrics. At the lesion-level, LOA95% was narrowest for iSUVmean at 1.00 (LOA95%: 0.88, 1.14), followed by iSUVmax at 1.00 (LOA95%: 0.76, 1.32), and iSUVtotal at 1.04 (LOA95%: 0.63, 1.71). At the patientlevel, the overall ratio between test-retest of pSUVmean was 0.99 (LOA95%: 0.89, 1.10), ratio of pSUVmax was 1.00 (LOA95%: 0.79, 1.26), and ratio of pSUVtotal was 1.00 (LOA95%: 0.70, 1.44), respectively. Across imaging metrics, LOA95% was consistently narrowest for SUVmean. Across sites, LOA95% was consistently narrowest, though not significantly different, for UWCCC.
A comparison of overall CV and ICC are shown in Fig. 5 . At both the lesion-and patient-levels, ICC was highest for iSUVtotal followed by iSUVmean and iSUVmax. Consistently, patient-level SUV metrics present lower CV than do lesion-level SUV metrics. Fig. 6 are Bland-Altman plots of lesion-level iSUVmax by site. MSKCC had statistically significantly different sample mean (p = .004) and UWCCC had significantly smaller variance (p < .001) as compared to the other two sites. In addition, the variance of iSUVmean (p < .001) and iSUVtotal (p < .001) at UWCCC were significantly smaller as compared to Sites 2 and 3. The sample mean of iSUVmean at MSKCC was differed significantly from the rest (p < .001).
Shown in
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DISCUSSION
This is the first multicenter study with results demonstrating the repeatability of multiple NaF PET SUV metrics, SUVmax, SUVmean, and SUVtotal, for both lesion-level and patient-level ROIs.
While different guidelines exist for the interpretation of ICC, one of the most common guidelines defines the range 0.40 < ICC < 0.75 as moderate repeatability, and > 0.75 as excellent repeatability (25). While 95% confidence intervals of ICC of SUVmax, SUVmean, and SUVtotal at the lesion-level were excellent for all sites, the 95% confidence intervals of the ICCs of pSUVmean and pSUVmax at MSKCC and NCI are not fully contained within the region of excellent repeatability. The target patient accrual goal was not met due to an imbalance of accrual between the two arms of therapy, thus decreasing statistical power for evaluating ICC.
In many cases in this study, there were multiple lesions per patient. As shown in the lesion-level Bland-Altman plots of iSUVmax in Fig. 6 , multiple lesions within the same patient have a tendency to show correlated repeatability. Thus, it is important to note that it was not possible to regard each lesion as independent. The intra-patient correlations were taken into account by implementing the Bland-Altman analysis for repeated measures (23).
Our repeatability results at the patient-level support those of the previous NaF PET study in bone lesions. At the patient-level, our findings show similar levels of repeatability for pSUVmax, pSUVmean, and pSUVtotal as compared to a study conducted by Kurdziel et al (18) . Despite the differences in lesion segmentation methods, our study shows similar ICC and CPD results for the three SUV metrics investigated in the Kurdziel study.
The application of both an uptake threshold and volume threshold were applied to minimize the probability of identifying benign disease. While Kurdziel et al used a segmentation threshold of SUV > 10, a later study by Rohren et al showed that ROIs identified with iSUVmax > by on October 21, 2017 . For personal use only. jnm.snmjournals.org Downloaded from 10 still included normal bone activity (19) . A study showed that iSUV max < 12 g/mL always represented a site of benign disease (26). Another study showed that iSUVmean of benign degenerative disease was 11.1 ± 3.8 g/mL (27). Therefore in this study, we applied the threshold of SUV > 15 to minimize the inclusion of benign disease. NaF PET findings demonstrated higher repeatability as compared to a multicenter study of 18 F-FDG PET imaging in patients with lung cancer and gastrointestinal malignancies (17) .
Patient effects such as respiratory motion may lead to increased random error in FDG PET of regions, to a greater effect in tissue than in bone structures (17) . In comparing the repeatability of SUV metrics, SUVmean was also found to be more repeatable than SUVmax of individual lesions (28).
One important aspect of this multicenter study was that although PET scans were acquired on different scanners with different acquisition parameters, the scanners were harmonized. Despite image harmonization, we found that UWCCC had significantly smaller variance in lesion-level test-retest measurements as compared to the other sites for all three imaging metrics. Rather, the repeatability differences between sites may be due to physiological factors such as circadian rhythm or different degrees of conformation to the imaging protocol 
patient-level such that LOA95% (α=0.05) can be applied to reflect true changes in uptake; percent decline in SUV less than the lower limit of LOA95% can be considered response, and increase in SUV greater than the upper limit can be considered progression.
CONCLUSION
Repeatability of NaF PET/CT-derived SUVmax, SUVmean, and SUVtotal were assessed for both lesion-and patient-level ROI in a multicenter prospective study in bone-metastatic CRPC.
Low repeatability coefficients, high intraclass correlation coefficients, and small coefficient of variations in test-retest scans were found. Patient-level repeatability was slightly superior to that of lesion-level, justifying the use of SUV both in individual lesions and across the whole body.
Results can be used to establish quantitative criteria for treatment response assessment using NaF PET in patients with bone-metastatic CRPC.
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